These medications: Compounded medications are not FDA-approved, and availability may vary
Human data remain limited and mixed, with dose, timing, and sex as key variables
L., Kahnt, T
In this context, it has been demonstrated that treatments with either a GLP1/Estrogen (GLP1/E) conjugate, a unimolecular GLP1/GIP (gastric inhibitory peptide) dual agonist, or a GLP1/GIP/Glucagon triagonist, markedly reduced body weight and improved diabetic complications, including hyperinsulinemia, in preclinical models of obesity in males 33,34,35
Theres also a practical problem: most biologics for RA come in fixed doses that arent adjusted for body weight
This analysis revealed 344 significantly upregulated genes